Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm Announces Key Executive Appointment

• Chief Medical Officer appointed

• Early clinical trial data leads to expanded clinical trial program

• Company prepares for pre-commercial phase

Sydney, 22 October 2018: Noxopharm (ASX:NOX) is pleased to announce the appointment of Dr Greg van Wyk as its Chief Medical Officer.

Dr van Wyk MB BCh BBA MEc is an experienced pharmaceutical industry physician who has led medical teams across Australasia and North-Western Europe. With postgraduate degrees in management and economics and experience working and leading across multiple therapeutic areas, he brings significant clinical and business acumen to this key role.

For further information please download PDF attached:
Download this document